Literature DB >> 25217165

CD8+ T cells prevent antigen-induced antibody-dependent enhancement of dengue disease in mice.

Raphaël M Zellweger1, William E Eddy1, William W Tang1, Robyn Miller1, Sujan Shresta2.   

Abstract

Dengue virus (DENV) causes pathologies ranging from the febrile illness dengue fever to the potentially lethal severe dengue disease. A major risk factor for developing severe dengue disease is the presence of subprotective DENV-reactive Abs from a previous infection (or from an immune mother), which can induce Ab-dependent enhancement of infection (ADE). However, infection in the presence of subprotective anti-DENV Abs does not always result in severe disease, suggesting that other factors influence disease severity. In this study we investigated how CD8(+) T cell responses influence the outcome of Ab-mediated severe dengue disease. Mice were primed with aluminum hydroxide-adjuvanted UV-inactivated DENV prior to challenge with DENV. Priming failed to induce robust CD8(+) T cell responses, and it induced nonneutralizing Ab responses that increased disease severity upon infection. Transfer of exogenous DENV-activated CD8(+) T cells into primed mice prior to infection prevented Ab-dependent enhancement and dramatically reduced viral load. Our results suggest that in the presence of subprotective anti-DENV Abs, efficient CD8(+) T cell responses reduce the risk of Ab-mediated severe dengue disease.
Copyright © 2014 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25217165      PMCID: PMC4185219          DOI: 10.4049/jimmunol.1401597

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  51 in total

1.  Strong HLA class I--restricted T cell responses in dengue hemorrhagic fever: a double-edged sword?

Authors:  H Loke; D B Bethell; C X Phuong; M Dung; J Schneider; N J White; N P Day; J Farrar; A V Hill
Journal:  J Infect Dis       Date:  2001-11-13       Impact factor: 5.226

Review 2.  Vaccine adjuvants: current state and future trends.

Authors:  Nikolai Petrovsky; Julio César Aguilar
Journal:  Immunol Cell Biol       Date:  2004-10       Impact factor: 5.126

3.  The TNFR family members OX40 and CD27 link viral virulence to protective T cell vaccines in mice.

Authors:  Shahram Salek-Ardakani; Rachel Flynn; Ramon Arens; Hideo Yagita; Geoffrey L Smith; Jannie Borst; Stephen P Schoenberger; Michael Croft
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

Review 4.  Dengue.

Authors:  Scott B Halstead
Journal:  Lancet       Date:  2007-11-10       Impact factor: 79.321

5.  Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification.

Authors:  Scott J Balsitis; Katherine L Williams; Ruben Lachica; Diana Flores; Jennifer L Kyle; Erin Mehlhop; Syd Johnson; Michael S Diamond; P Robert Beatty; Eva Harris
Journal:  PLoS Pathog       Date:  2010-02-12       Impact factor: 6.823

Review 6.  Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development.

Authors:  Theodore C Pierson; Daved H Fremont; Richard J Kuhn; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2008-09-11       Impact factor: 21.023

7.  Dengue virus infections and maternal antibody decay in a prospective birth cohort study of Vietnamese infants.

Authors:  Tran Nguyen Bich Chau; Nguyen Trong Hieu; Katherine L Anders; Marcel Wolbers; Le Bich Lien; Lu Thi Minh Hieu; Tran Tinh Hien; Nguyen Thanh Hung; Jeremy Farrar; Stephen Whitehead; Cameron P Simmons
Journal:  J Infect Dis       Date:  2009-12-15       Impact factor: 5.226

8.  Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells.

Authors:  Zhihua Kou; Matthew Quinn; Huiyuan Chen; W W Shanaka I Rodrigo; Robert C Rose; Jacob J Schlesinger; Xia Jin
Journal:  J Med Virol       Date:  2008-01       Impact factor: 2.327

Review 9.  Neurological complications of dengue virus infection.

Authors:  Francisco Javier Carod-Artal; Ole Wichmann; Jeremy Farrar; Joaquim Gascón
Journal:  Lancet Neurol       Date:  2013-09       Impact factor: 44.182

10.  Protective and enhancing HLA alleles, HLA-DRB1*0901 and HLA-A*24, for severe forms of dengue virus infection, dengue hemorrhagic fever and dengue shock syndrome.

Authors:  Thi Phuong Lan Nguyen; Mihoko Kikuchi; Thi Que Huong Vu; Quang Ha Do; Thi Thuy Tran; Dinh Tham Vo; Manh Tuan Ha; Van Tuong Vo; Thi Phi Nga Cao; Van Dat Tran; Toshifumi Oyama; Kouichi Morita; Michio Yasunami; Kenji Hirayama
Journal:  PLoS Negl Trop Dis       Date:  2008-10-01
View more
  51 in total

1.  Challenge accepted: Human challenge trials for dengue.

Authors:  Wudan Yan
Journal:  Nat Med       Date:  2015-08       Impact factor: 53.440

2.  Mapping and Role of the CD8+ T Cell Response During Primary Zika Virus Infection in Mice.

Authors:  Annie Elong Ngono; Edward A Vizcarra; William W Tang; Nicholas Sheets; Yunichel Joo; Kenneth Kim; Matthew J Gorman; Michael S Diamond; Sujan Shresta
Journal:  Cell Host Microbe       Date:  2017-01-11       Impact factor: 21.023

3.  Immunodominant Dengue Virus-Specific CD8+ T Cell Responses Are Associated with a Memory PD-1+ Phenotype.

Authors:  Ruklanthi de Alwis; Derek J Bangs; Michael A Angelo; Cristhiam Cerpas; Anira Fernando; John Sidney; Bjoern Peters; Lionel Gresh; Angel Balmaseda; Aruna D de Silva; Eva Harris; Alessandro Sette; Daniela Weiskopf
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

Review 4.  Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? Questions Raised by the Development and Implementation of Dengue Vaccines: Example of the Sanofi Pasteur Tetravalent Dengue Vaccine.

Authors:  Bruno Guy
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

Review 5.  Antigenic cross-reactivity between Zika and dengue viruses: is it time to develop a universal vaccine?

Authors:  Jinsheng Wen; Sujan Shresta
Journal:  Curr Opin Immunol       Date:  2019-03-15       Impact factor: 7.486

6.  Dengue-specific CD8+ T cell subsets display specialized transcriptomic and TCR profiles.

Authors:  Yuan Tian; Mariana Babor; Jerome Lane; Grégory Seumois; Shu Liang; N D Suraj Goonawardhana; Aruna D De Silva; Elizabeth J Phillips; Simon A Mallal; Ricardo da Silva Antunes; Alba Grifoni; Pandurangan Vijayanand; Daniela Weiskopf; Bjoern Peters; Alessandro Sette
Journal:  J Clin Invest       Date:  2019-03-18       Impact factor: 14.808

Review 7.  T Cell Immunity to Zika and Dengue Viral Infections.

Authors:  Jinsheng Wen; Sujan Shresta
Journal:  J Interferon Cytokine Res       Date:  2017-11       Impact factor: 2.607

Review 8.  Mouse models of dengue virus infection for vaccine testing.

Authors:  Vanessa V Sarathy; Gregg N Milligan; Nigel Bourne; Alan D T Barrett
Journal:  Vaccine       Date:  2015-10-23       Impact factor: 3.641

9.  Antibody-Dependent Enhancement of Severe Disease Is Mediated by Serum Viral Load in Pediatric Dengue Virus Infections.

Authors:  Jesse J Waggoner; Leah C Katzelnick; Raquel Burger-Calderon; Julia Gallini; Renee H Moore; Guillermina Kuan; Angel Balmaseda; Benjamin A Pinsky; Eva Harris
Journal:  J Infect Dis       Date:  2020-05-11       Impact factor: 5.226

10.  Synergism between the tyrosine kinase inhibitor sunitinib and Anti-TNF antibody protects against lethal dengue infection.

Authors:  Emilie Branche; William Weihao Tang; Karla M Viramontes; Matthew Perry Young; Nicholas Sheets; Yunichel Joo; Anh-Viet T Nguyen; Sujan Shresta
Journal:  Antiviral Res       Date:  2018-07-30       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.